Hikma Pharmaceuticals (OTCMKTS:HKMPF) Upgraded at Royal Bank of Canada

Royal Bank of Canada upgraded shares of Hikma Pharmaceuticals (OTCMKTS:HKMPF) from a hold rating to a moderate buy rating in a research note released on Tuesday,Zacks.com reports.

Hikma Pharmaceuticals Stock Performance

HKMPF stock opened at $24.87 on Tuesday. The company has a fifty day moving average price of $24.48 and a 200 day moving average price of $24.92. The company has a current ratio of 1.66, a quick ratio of 0.98 and a debt-to-equity ratio of 0.46. Hikma Pharmaceuticals has a 12 month low of $21.90 and a 12 month high of $26.50.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.